All three have COVID-19 connections.
Compare BNTX Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: BioNTech SE
BioNTech and Pfizer announced high efficacy for their COVID-19 vaccine booster.
One biotech CEO thinks so.
The move downward follows yet more good news from rivals.
Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.
Volatility remains high among vaccine stocks as two CEOs predict the end of the pandemic next year.
With its latest ruling on the biotech's coronavirus vaccine, the FDA boosts the investment case for the stock.
The stock's valuation skeptics might be underestimating the coronavirus.
Booster shots of its vaccine will be part of an important anti-COVID push in the U.K.
There's more good news on the way for these two coronavirus vaccine developers.